Novel Antiviral Molecules against Ebola Virus Infection - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles International Journal of Molecular Sciences Year : 2023

Novel Antiviral Molecules against Ebola Virus Infection


Infection with Ebola virus (EBOV) is responsible for hemorrhagic fever in humans with a high mortality rate. Combined efforts of prevention and therapeutic intervention are required to tackle highly variable RNA viruses, whose infections often lead to outbreaks. Here, we have screened the 2P2I3D chemical library using a nanoluciferase-based protein complementation assay (NPCA) and isolated two compounds that disrupt the interaction of the EBOV protein fragment VP35IID with the N-terminus of the dsRNA-binding proteins PKR and PACT, involved in IFN response and/or intrinsic immunity, respectively. The two compounds inhibited EBOV infection in cell culture as well as infection by measles virus (MV) independently of IFN induction. Consequently, we propose that the compounds are antiviral by restoring intrinsic immunity driven by PACT. Given that PACT is highly conserved across mammals, our data support further testing of the compounds in other species, as well as against other negative-sense RNA viruses.
Fichier principal
Vignette du fichier
ijms-24-14791-v2.pdf (3.6 Mo) Télécharger le fichier
Origin Publication funded by an institution

Dates and versions

hal-04628707 , version 1 (08-07-2024)




Mila Collados Rodríguez, Patrick Maillard, Alexandra Journeaux, Anastassia Komarova, Valérie Najburg, et al.. Novel Antiviral Molecules against Ebola Virus Infection. International Journal of Molecular Sciences, 2023, 24 (19), pp.14791. ⟨10.3390/ijms241914791⟩. ⟨hal-04628707⟩
0 View
0 Download



Gmail Mastodon Facebook X LinkedIn More